home / compounds / Cagrilintide
Cagrilintide
AM833
REC PPT-CAGRILINTIDE // REV 2026-10-04 // assessment changes are logged, never silent
Amylin analogue, mainly studied combined with semaglutide.
What it is
A long-acting amylin analogue investigated largely as a combination therapy.
What it does
Amylin signalling contributes to satiety through a pathway distinct from GLP-1, which is the rationale for combining the two.
Does it work?
Clinical development is ongoing, mostly as part of a combination product. Standalone evidence is thinner than the combination data.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Promotes satiety through the amylin pathway | supported |
| Adds weight loss when combined with semaglutide | partially true |
| Proven as a standalone weight-loss therapy | weak evidence |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
molecular data — PubChem CID 171397054
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
463 publications indexed, but only 19 randomised controlled trials and 45 registered interventional studies. Human evidence exists but is thin.
SRC // EUROPE PMC + CTGOV // "Cagrilintide" // FETCHED 2026-10-04 // 463 RECORDS
Most-cited literature
-
[01]
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. · Signal Transduct Target Ther 2024 · 826 citations · DOI 10.1038/s41392-024-01931-z
-
[02]
Anti-obesity drug discovery: advances and challenges
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. · Nat Rev Drug Discov 2022 · 731 citations · DOI 10.1038/s41573-021-00337-8
-
[03]
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. · BMJ 2024 · 449 citations · DOI 10.1136/bmj-2023-076410
-
[04]
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker DJ. · Mol Metab 2022 · 400 citations · DOI 10.1016/j.molmet.2021.101351
Regulatory status
Formal, dated regulatory actions.
WADA — Prohibited List 2026
Prohibited in sport — WADA S0 (substance without any health-authority approval)
Common questions
What is CagriSema?
The clinical combination of cagrilintide with semaglutide, developed as a single weekly product. Most cagrilintide evidence comes from this programme.
Does cagrilintide work on its own?
Standalone data is thinner than the combination data. The amylin pathway is a real satiety mechanism, but the strong results reported are largely combination results.
Is it approved anywhere?
Not as of our last review. It remains in clinical development.
Related compounds
Semaglutide
GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.
Tirzepatide
Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.
Retatrutide
Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.